http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Abbott′s FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe
-
Abbott Receives CE Mark for First Troponin Test to Help Predict the Chance of Heart Attack in Apparently Healthy Adults Potentially Months to Years in Advance
-
One-Year Results from Real-World Study Showed Abbott's Portico™ Transcatheter Aortic Valve Safely and Successfully Reduced Severe Aortic Stenosis
-
Abbott (ABT) Reports Positive Clinical Study Results from Randomized Controlled Trial Comparing Treatment with MitraClip Device
-
Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation
-
Abbott Hosts Conference Call for Third-Quarter Earnings
-
Abbott Declares 379th Consecutive Quarterly Dividend
-
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
-
New Coverage Decision Extends Abbott's Innovative Pain Therapy Option to 22 Million Americans Living with Chronic Pain
-
Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling
-
Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S.
-
Abbott Begins U.S. Pivotal Trial for the Tendyne Mitral Valve Replacement System to Treat Patients with Heart Valve Disease
-
Abbott Reports Second-Quarter 2018 Results
-
Abbott (ABT) Announces FDA Approval for Next-Generation MitraClip Device to Treat People with Leaky Heart Valves
-
Abbott Receives FDA Approval for Next-Generation MitraClip® Device to Treat People with Leaky Heart Valves
-
Abbott Announces Freedom 2 Save Program for Employees to Address Student Debt
-
Abbott (ABT) Says New Late-Breaking Data at ADA Underscore Significant Benefits of its FreeStyle Libre System
-
New Late-Breaking Data at ADA Underscore Significant Benefits of Abbott's FreeStyle Libre System for People Living with Diabetes
-
Abbott Hosts Conference Call for Second-Quarter Earnings
-
Abbott Declares 378th Consecutive Quarterly Dividend
-
Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management
-
Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
-
Abbott (ABT) Reports Positive Outcomes for First 100 Patients in Global Study of Investigational Tendyne Transcatheter Mitral Valve Replacement System
-
Abbott's Investigational Tendyne™ Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study
-
Abbott (ABT) Reports 5-Yr FAME 2 Study Showing Positive Outcomes of Patients Using Diagnostic Tool
-
Five-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting Decisions
-
Abbott (ABT) Announces FDA Clearance of Advanced Mapping Catheter
-
Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
-
Abbott's XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease
-
Sanquin Selects Abbott's "Alinity™ s" Solution for Blood and Plasma Screening
-
Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023
-
Abbott Reports First-Quarter 2018 Results
-
Abbott's New Ensure® Max Protein Helps Americans Go for Their #HealthGoals
-
Abbott (ABT) Initiates Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease
-
Abbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease
-
Abbott (ABT) Initiates Trial to Look at Improved Survival, Outcomes with CardioMEMS Monitor
-
Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor
-
Abbott Hosts Conference Call for First-Quarter Earnings
-
Abbott's MitraClip Therapy Receives National Reimbursement in Japan to Treat Patients with Mitral Regurgitation
-
New Long-Term Data Show Improved Survival and Lower Rates of Stroke and Pump Thrombosis for Abbott's HeartMate 3 Heart Pump
-
Abbott (ABT) Reports FDA Approval of Masters HP 15mm Rotatable Mechanical Heart Valve
-
FDA Approves the World's Smallest Mechanical Heart Valve for Pediatric Patients with Heart Defects
-
Abbott to Present at the Barclays Capital 2018 Global Healthcare Conference
-
Abbott (ABT), Surmodics (SRDX) Announce Pact for Next-Generation Drug-Coated Balloon
-
Abbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon
-
Abbott Declares 377th Consecutive Quarterly Dividend
-
Abbott's App for FreeStyle® Libre System Now Available in Europe for Both iPhone™ and Android™
-
Abbott Reports Fourth-Quarter 2017 Results
-
Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle® Libre, Now Available To Medicare Patients
-
Abbott (ABT) Announces New FDA MR-Conditional Labeling Approvals Further Expand its Portfolio of MRI-Ready Devices

